Clinical Trial Update: A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation [Phase 2]

View source ↗

Summary

A pilot Phase 2 trial evaluated GI-4000, an inactivated recombinant yeast expressing mutant Ras, as consolidation therapy after curative treatment for Stage I-I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GI-4000

Snippet

Sponsor: GlobeImmune | Conditions: NSCLC | Phase 2 | Status: COMPLETED